There are multiple ways to win in the stock market. Traditional "value investing" brings to mind beaten-down stocks with low P/E ratios that are trading below net current asset value. But at the right price, value can be found in all sortsI am a software developer by trade who focuses on finding value in the market wherever it may lie. I'm looking mainly in small caps for opportunities that provide asymmetric upside. I'm also interested in generating income through my investments, which leads me to look at ...

The company's performance has been more consistent than the stock price.Coupang (CPNG 3.88%) is a growing e-commerce company capitalizing on a significant opportunity to expand across Asia. It's headquartered in Seattle but dominates the South Korean market and has an expanding operation in Taiwan.The stock was trading at an expensive valuation following its 2021 initial public offering. This explains why the shares have declined by 45% over the past five years, underperforming the S&P 500's 74% gain over t ...

We came across a bullish thesis on FedEx Corporation on Quality Value Investing’s Substack by David J. Waldron. In this article, we will summarize the bulls’ thesis on FDX. FedEx Corporation's share was trading at $273.34 as of December 1st. FDX’s trailing and forward P/E were 16.02 and 15.11 respectively according to Yahoo Finance. FedEx Corporation (FDX) Has A Warehouse With No People, Says Jim Cramer FedEx Corporation (FDX) is a large-cap, dividend-paying industrials stock operating globally in air fr ...

Teva Pharmaceutical Industries FY Conference Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **Date of Conference**: December 03, 2025 Key Points Industry and Product Insights - **Austedo Pricing**: Teva successfully positioned Austedo at the lowest price on the HHS list, which was a strategic decision based on thorough justification and stakeholder engagement [1][2] - **Intellectual Property (IP) Timeline**: The IP for the once-daily formulation of Austedo extends to 2040-2041, while the BID formulation is set to expire in 2033. Teva anticipates a smooth transition to the XR formulation [2] - **Product Pipeline**: By 2033, Teva expects to have multiple products in the market, including Uzedy, olanzapine, Emrysulmin, and Duvakitug, indicating a diversified product portfolio beyond Austedo [2][3] Financial Performance and Projections - **EBITDA Growth**: Teva aims to drive EBITDA growth through innovative products, with expectations of Austedo contributing significantly through the 2030s [3][4] - **2026 Financial Outlook**: Teva anticipates a decline in revenue due to the loss of Revlimid revenue but is committed to growing EBITDA and cash flow in 2026. The innovative portfolio grew by 33% in Q3, contributing over $800 million quarterly [10][11] - **Cost Savings Program**: Teva is on track to achieve two-thirds of its $700 million savings target by the end of 2026, with significant headcount reductions planned [12][13] Product Launches and Market Strategy - **Olanzapine Launch**: Teva is preparing for the launch of long-acting olanzapine, emphasizing the importance of obtaining the right label from the FDA to maximize market potential. The product is expected to generate $1.5-$2 billion in revenue [14][15][20] - **Market Positioning**: Unlike Austedo, which faced a competitive landscape, olanzapine will enter a market with no incumbent brands, presenting a significant opportunity for growth [20][21] Future Growth and Investment Grade Aspirations - **EBITDA Aspirations**: Teva projects that EBITDA could exceed $6 billion, driven by successful product launches and a disciplined approach to operational expenses [26][28] - **Investment Grade Status**: Teva aims to achieve investment-grade status by the second half of next year, supported by diligent debt repayment and EBITDA growth [28][29] Additional Considerations - **Patient Compliance**: Teva's products, including Uzedy and olanzapine, target a significant portion of the schizophrenia patient population, emphasizing the importance of compliance for treatment efficacy [24] - **Securitization and Cash Flow**: Teva's cash flow is projected to reach approximately $2.7 billion by 2027 and over $3 billion by 2030, indicating a strong financial trajectory [32] This summary encapsulates the critical insights from Teva Pharmaceutical Industries' FY conference, highlighting the company's strategic positioning, financial outlook, and product pipeline developments.

Core Insights - TELUS Corporation has announced a pause in dividend growth and plans to step down its Discounted Dividend Reinvestment Plan (DRIP) starting in early 2026, while maintaining its current quarterly dividend of $0.4184 per share [1] - The company aims to reduce its net debt to EBITDA leverage ratio to approximately 3 times by the end of 2027, with an expected improvement to about 3.3 times by the end of 2026 [1] - TELUS projects a minimum 10% compounded annual growth rate in free cash flow from 2026 to 2028, with an anticipated free cash flow of approximately $2.15 billion in 2025 and $2.4 billion in 2026 [1] Financial Strategy - The company plans to systematically reduce its Discounted DRIP from 2% to 1.75% for dividends declared in February and May 2026, further decreasing to 1.5% for dividends in August and November 2026, and to 1% in 2027, with no discount starting in 2028 [1] - TELUS expects a cash dividend coverage ratio of approximately 75% of free cash flow for the years 2026 to 2028, aligning with its long-term guidelines [1] Business Operations - TELUS is focusing on strategic partnerships, including a potential partner for TELUS Health, and plans to accelerate the monetization of significant real estate and copper assets [1] - The company has improved its leverage ratio to 3.5 times as of September 30, 2025, aided by partnerships, hybrid note issuances, and non-core asset divestitures [1]

Core Viewpoint - Chevron has established itself as a leading dividend stock, having increased its dividend for 38 consecutive years, with a compound annual growth rate of 7% over the past 25 years and 5% over the last decade, despite oil price volatility [1][4]. Group 1: Dividend Growth and Financial Strength - Chevron anticipates over 10% annual growth in adjusted free cash flow and earnings per share through 2030, assuming Brent oil averages around $70 per barrel [4]. - Among the 100 largest companies in the S&P 500, only 35 expect to achieve more than 10% annual earnings per share and free cash flow growth through 2027, with Chevron being the only one in that group offering a dividend yield above 4% [5]. Group 2: Growth Drivers - Chevron's growth strategy is supported by a robust five-year plan, focusing on low-cost upstream oil and gas operations, and strategic acquisitions, including the recent acquisition of Hess [6][7]. - The company has multiple expansion projects underway, including the $6.8 billion Hammerhead project and the Longtail project expected to come online by 2030 [8].

Core Insights - Workday, Inc (NASDAQ:WDAY) demonstrates strong deal momentum, particularly in commercial, healthcare, and financial services sectors, leading to a maintained Buy rating with a price target of $265 [1][2]. Group 1: Financial Performance - The analyst projects a 16.5% growth in current remaining performance obligation (cRPO) for the third quarter, with a similar expectation of 15.5% growth for the fourth quarter year-over-year [3]. - Anticipated margins for the third quarter and fiscal 2026 are 28% and 28.9%, respectively, with expectations of a beat-and-raise quarter as the company aims for a 35% operating margin by fiscal 2028 [3][4]. Group 2: Market Trends and Demand - There is a noted increase in demand for human capital management (HCM) solutions, including add-on products like Extend and talent-acquisition tools, alongside improving trends in Europe [2][4]. - The company is expected to achieve solid free cash flow growth, alleviating earlier investor concerns regarding AI disruption and growth targets [4][5]. Group 3: Long-term Outlook - Workday's updated long-term goals of 12% to 15% revenue growth and 35% margins support a credible free cash flow growth model, with potential for multiple expansion as the stock trades at 14 times calendar 2027 free cash flow [5]. - The company is positioned for healthy growth through international expansion, mid-market wins, and platform deals, which are expected to enhance investor confidence [6].

Core Insights - Northrop Grumman Corporation has a market capitalization of $82 billion and has reported a strong performance in 2025 with 5% organic growth and healthy margin expansion [1] - The company is experiencing robust free cash flow growth and has indicated a path to double its free cash flow by 2028 [1] - Northrop Grumman's projected mid-single-digit organic growth for the next year is expected to outperform its peers [1] Company Performance - The company reported a 5% organic growth for the year [1] - There has been significant margin expansion contributing to overall financial health [1] - Free cash flow growth is described as robust, indicating strong liquidity and operational efficiency [1] Future Outlook - Northrop Grumman is on track to double its free cash flow by 2028, suggesting a strong long-term growth strategy [1] - The company anticipates mid-single-digit organic growth for the upcoming year, which is positioned above its peers [1]

Financial Data and Key Metrics Changes - The company confirmed its guidance for Q4, albeit at the low end, expecting a top-line decline of between -1.5% and -2% [19] - Year-to-date sellout growth is reported at +0.2%, with the last three months showing a value growth of +0.5% and volume growth of +0.7% [20][40] - The company is actively working on a €200 million multi-year efficiency target, which remains a priority [6][10] Business Line Data and Key Metrics Changes - The company is focusing on improving product quality in its pizza business in the UK, with early positive signals from a new campaign launched in September [20] - Renovation efforts are underway for key products such as fish fingers and pizza, which are expected to enhance competitiveness against private labels [26][27] Market Data and Key Metrics Changes - The company has observed a slight decrease in its price index compared to private label competitors, which has been beneficial in the context of necessary price increases [9] - The competitive landscape is evolving, with private labels improving in quality and innovation, prompting the company to enhance its value proposition [23][26] Company Strategy and Development Direction - The company is committed to a holistic approach for pricing and product renovation, aiming to balance cost increases with maintaining market share [30][32] - The focus remains on cash flow growth and reducing exceptional items while driving a competitiveness program [6][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced this year, including weather impacts and a less favorable ice cream season, but expresses confidence in recovery and improvement [19][40] - The incoming CEO is expected to build upon the foundation laid by the current management, with optimism for future performance [47] Other Important Information - The company plans to continue share buybacks, especially given the current low price-to-earnings ratio, indicating a belief in the intrinsic value of the company [43] - The management has emphasized the importance of not being complacent in the competitive frozen food category, focusing on both pricing and non-pricing factors [24][26] Q&A Session Summary Question: Are the medium-term goals still relevant after the CEO change? - Management reassured that the commitments regarding efficiency targets and EBITDA growth remain intact despite the leadership change [6][7] Question: How is the company balancing pricing with market share? - The company noted that while private labels have caught up slightly in pricing, they are implementing a cost competitiveness program to help manage inflation and maintain market share [9][10] Question: What are the expectations for 2026? - Management indicated that while it is too early to provide specific guidance for 2026, they expect results to improve compared to 2025 [16][17] Question: What factors could impact Q4 results? - Management highlighted that pricing decisions and competition dynamics would be key factors influencing Q4 performance [21] Question: How is private label competition evolving? - Management acknowledged that private labels are improving in quality and innovation, necessitating a stronger value proposition from the company [23][26] Question: What drove the decision to delay repricing? - The decision was based on a more stable cost environment compared to previous years, avoiding unnecessary negotiations [31][32] Question: What are the capital allocation priorities? - The company plans to prioritize share buybacks and dividends, supported by recent refinancing efforts [41][43]

Group 1 - The FPA Crescent Fund gained 5.54% in Q3 2025 and 15.32% over the trailing twelve months, with top five performers contributing 6.65% and bottom five detracting 2.58% from the returns [1] - International Flavors & Fragrances Inc. (NYSE:IFF) is a key holding in the fund, with a one-month return of 6.40% but a significant decline of 29.64% over the past 52 weeks, closing at $64.00 per share and a market capitalization of $16.39 billion [2][3] Group 2 - IFF is a major producer of ingredients for various industries, including food and beverage, with its products being essential in many household items [3] - The company has faced challenges due to previous management's poor capital allocation and acquisitions, which led to lower margins and increased leverage [3] - A new CEO is focusing on operational excellence and divesting non-core assets, which is expected to reduce leverage and improve margins [3] - Current free cash flow of approximately $4 is projected to increase to $5-6 in a few years, potentially leading to a higher P/E ratio in line with peers [3] - The stock price, currently at $61, has a potential path to double if the company executes its strategy effectively [3]